Medicare Enrolled
Dr. Craig Reynolds, M.D.
Hematology · Ocala, FL
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Reynolds from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Reynolds?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Reynolds
Dr. Craig Reynolds is a hematology specialist in Ocala, FL, with 20 years of NPI registration. Based on federal Medicare data, Dr. Reynolds performed 81,784 Medicare services across 2,615 unique beneficiaries.
Between the years covered by Open Payments, Dr. Reynolds received a total of $54,145 from 69 pharmaceutical and/or device companies across 499 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Reynolds is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ 81,784 Medicare services
$54,145 industry payments
Medicare Practice Summary
Medicare Utilization ↗81,784
Medicare services
Bottom 48% in FL for hematology
2,615
Unique beneficiaries
$8
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~4,089 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) An injection of ferumoxytol used to treat iron deficiency anemia in patients not on dialysis. |
46,410 | $0 | $4 |
| Denosumab injection (Prolia/Xgeva) | 13,800 | $18 | $51 |
| Anti-nausea injection (aprepitant) | 5,330 | $1 | $5 |
| Immune globulin infusion (Gammagard) An injection of immune globulin (Gammagard Liquid) to provide antibodies. The dose specified is 500 mg. |
4,272 | $36 | $108 |
| Epoetin alfa injection (Procrit) for anemia An injection of epoetin alfa containing 1000 units for use in patients not on end-stage renal disease (ESRD) dialysis. |
3,080 | $6 | $23 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
1,422 | $8 | $9 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
1,362 | $8 | $29 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,209 | $0 | $3 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
678 | $65 | $239 |
| Anti-nausea injection (Aloxi/palonosetron) | 670 | $1 | $28 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
595 | $10 | $69 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
540 | $95 | $339 |
| Anti-nausea injection (ondansetron/Zofran) | 384 | $0 | $9 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
366 | $12 | $61 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
238 | $97 | $378 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
227 | $1 | $6 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
222 | $46 | $189 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
121 | $1 | $3 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
100 | $15 | $56 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
76 | $27 | $156 |
| Methylprednisolone injection, up to 40 mg An injection of methylprednisolone sodium succinate, a corticosteroid medication, administered in a dose of up to 40 mg. |
75 | $3 | $11 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
71 | $21 | $79 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
62 | $83 | $298 |
| Hospital follow-up visit, low complexity Follow-up hospital visit for an established patient with straightforward or low-level medical decision making. The visit requires at least 25 minutes of time spent on the day of service. |
52 | $40 | $109 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
51 | $49 | $178 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
49 | $135 | $556 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
46 | $22 | $84 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
46 | $2 | $7 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
42 | $140 | $474 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
37 | $10 | $42 |
| Automated urinalysis An automated laboratory test performed on a urine sample to analyze its chemical and physical properties. The procedure uses machinery to detect various substances and cells within the urine. |
34 | $2 | $8 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
32 | $60 | $197 |
| Office visit for established patient An office visit for an existing patient that may not require the healthcare professional to be present. |
29 | $14 | $59 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
23 | $103 | $377 |
| Automated red blood cell count An automated laboratory test that measures the number of red blood cells in a blood sample. |
18 | $4 | $10 |
| New patient office visit, complex (60-74 min) | 15 | $173 | $585 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
62.8% high complexity
31.8% medium
5.4% routine
Industry Payment Transparency
Open Payments through 2024 ↗$54,145
Total received (2018-2024)
Avg $7,735/year across 7 years
Top 11% in FL for hematology
69
Companies
499
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$31,092 (57.4%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$16,302 (30.1%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$6,752 (12.5%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$166
2023
$3,757
2022
$905
2021
$1,329
2020
$3,299
2019
$8,026
2018
$36,663
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Merck Sharp & Dohme Corporation
$24,429
E.R. Squibb & Sons, L.L.C.
$7,509
Genentech USA, Inc.
$6,163
Lilly USA, LLC
$5,655
AstraZeneca Pharmaceuticals LP
$3,512
Celgene Corporation
$979
Janssen Biotech, Inc.
$731
Novartis Pharmaceuticals Corporation
$658
Amgen Inc.
$400
Octapharma USA, Inc.
$308
PFIZER INC.
$300
Daiichi Sankyo Inc.
$261
GENZYME CORPORATION
$257
Seagen Inc.
$254
Bayer HealthCare Pharmaceuticals Inc.
$222
Incyte Corporation
$183
Astellas Pharma US Inc
$178
GlaxoSmithKline, LLC.
$126
EMD Serono, Inc.
$98
Foundation Medicine, Inc.
$96
Eisai Inc.
$90
Seattle Genetics, Inc.
$88
Clovis Oncology, Inc.
$77
Aurobindo Pharma USA, Inc.
$77
Karyopharm Therapeutics Inc.
$75
EISAI INC.
$75
Takeda Pharmaceuticals U.S.A., Inc.
$73
AMAG Pharmaceuticals, Inc.
$71
Heron Therapeutics, Inc.
$63
JAZZ PHARMACEUTICALS INC.
$61
Puma Biotechnology, Inc.
$57
Myriad Genetic Laboratories, Inc.
$55
Array BioPharma Inc.
$53
Agios Pharmaceuticals, Inc.
$52
ABBVIE INC.
$52
Sun Pharmaceutical Industries Inc.
$50
Pharmacyclics LLC, An AbbVie Company
$48
Kite Pharma, Inc.
$45
Tempus AI, Inc
$44
Alexion Pharmaceuticals, Inc.
$39
PUMA BIOTECHNOLOGY, INC.
$39
Lexicon Pharmaceuticals, Inc.
$38
Dendreon Pharmaceuticals LLC
$38
TerSera Therapeutics LLC
$36
Boehringer Ingelheim Pharmaceuticals, Inc.
$31
Regeneron Healthcare Solutions, Inc.
$29
Pharmacyclics LLC, an AbbVie Company
$28
Blueprint Medicines Corporation
$25
ARRAY BIOPHARMA INC
$25
Emmaus Medical, Inc.
$24
Secura Bio, Inc.
$23
Merck Sharp & Dohme LLC
$22
CSL Behring
$19
INSYS Therapeutics Inc
$18
BeiGene USA, Inc.
$18
AbbVie, Inc.
$18
Jazz Pharmaceuticals Inc.
$16
SANOFI-AVENTIS U.S. LLC
$14
Exelixis Inc.
$14
CTI BioPharma Corp.
$14
Tactile Systems Technology Inc
$13
AVEO Pharmaceuticals, Inc.
$12
NanoString Technologies, Inc.
$12
AbbVie Inc.
$12
Gilead Sciences, Inc.
$12
Verastem, Inc.
$11
GE HEALTHCARE
$10
GE HealthCare
$10
Veracyte, Inc.
$1
Top 3 companies account for 70.4% of total payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · ALIMTA · AYVAKIT · Abraxane · Alecensa · Aliqopa · Avastin · BLENREP · BOSULIF · BRACANALYSIS CDX · BRAFTOVI · BRUKINSA · Balversa · Bavencio · Blincyto · Braftovi · CABLIVI · CEREZYME · CINVANTI · CYRAMZA · Cabometyx · Cinvanti · Copiktra · DARZALEX · ELIQUIS · ELITEK · EPKINLY · Endari · Enhertu · Erleada · FARYDAK · FERAHEME · FOTIVDA · FOUNDATIONONE · Farydak · Flexitouch Plus · GAUCHER-DISEASE · GAVRETO · GAZYVA · GILOTRIF · Gazyva · Halaven · IBRANCE · IDHIFA · IMBRUVICA · IMFINZI · INJECTAFER · INREBIC · Idelvion · Imbruvica · Inrebic · JAKAFI · JEVTANA · KEYTRUDA · KISQALI · Kyprolis · LIBTAYO · LUTATHERA · LYNPARZA · Lenvima · MEKINIST · MVASI · MYRISK · NERLYNX · NINLARO · Neulasta · Nexavar · OCTAGAM IMMUNE GLOBULIN (HUMAN) · ODOMZO · OPDIVO · OPDUALAG · PADCEV · PIQRAY · PROMACTA · PROSIGNA ASSAY · PROVENGE · Perjeta · Phesgo · Polivy · Pomalyst · Prolia · REBLOZYL · RYBREVANT · RYDAPT · Revlimid · Rubraca · SARCLISA · SCEMBLIX · SOLIRIS · SUSTOL · SYNDROS · Stivarga · TABRECTA · TAGRISSO · TECENTRIQ · TIBSOVO · TIVDAK · TUKYSA · Tarceva · Ultomiris · VENCLEXTA · VOTRIENT · Venclexta · Vitrakvi · Vonjo · XALKORI · XGEVA · XOSPATA · XPOVIO · XT CDX · XTANDI · Xermelo · Xofigo · YONSA · ZEJULA · ZEPZELCA · ZOLADEX · Zevalin · myRisk
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (57%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in hematology and does not inherently indicate bias, but patients may wish to be aware.
Equivalent to $66 per 100 Medicare services performed
Geographic Context
Hematologists within 10 mi
9
Per 100K population
2.3
County median income
$58,535
Nearest hospital
MARION COMMUNTIY HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Reynolds is a mixed practice specialist, with moderate Medicare volume, with speaking/promotional industry engagement in the top 11% of FL peers, with 20 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Reynolds experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Reynolds performed 46,410 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Reynolds receive payments from pharmaceutical companies?
Yes. Dr. Reynolds received a total of $54,145 from 69 companies across 499 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Reynolds's costs compare to other hematologists in Ocala?
Dr. Reynolds's average Medicare payment per service is $8. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Reynolds) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematologists in Ocala
Browse hematologists in Ocala ranked by procedure volume and transparency data.
Highest volume
Top Hematologists in FL
Hematologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematologists in FL
Which FL hematologists receive the most from drug and device companies.
By company
Merck Sharp & Dohme Corporation Payments to Doctors
See all physicians who received payments from Merck Sharp & Dohme Corporation.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
Genentech USA, Inc. Payments to Doctors
See all physicians who received payments from Genentech USA, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology